# EDGAR Filing Document

**Accession Number:** 0002091349
**File Stem:** 0001478916-26-000005
**Filing Date:** 2026-4
**Character Count:** 12777
**Document Hash:** f7e21092c8fd5201ab6fef5eed22497c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001478916-26-000005.hdr.sgml**: 20260422

**ACCESSION NUMBER**: 0001478916-26-000005

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260420

**FILED AS OF DATE**: 20260422

**DATE AS OF CHANGE**: 20260422

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schmid John P.
- **CENTRAL INDEX KEY:** 0001478916

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43177
- **FILM NUMBER:** 26883734

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** First Tracks Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0002091349
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 395003207
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 212-373-3000

**MAIL ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE
- **STREET 2:** SUITE 210
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biopharma Company, Inc.
- **DATE OF NAME CHANGE:** 20251010

## Ex-24

**<u>POWER OF ATTORNEY</u>**

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Dan Faga, Ajim Tamboli and Dave McKeon, and each of them, her true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of First Tracks Biotherapeutics, Inc. ("***Company***"), any and all Form 3, 4 or 5 reports required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended ("***Exchange Act***"), and the rules thereunder with respect to transactions in securities of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 report and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneyin-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneyin-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorneyin-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the 14<sup>th</sup> day of April, 2026.

<u>/s/ John Schmid</u>

Name: John Schmid

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schmid John P.<br><sub>(Last) (First) (Middle)</sub><br>10770 WATERIDGE CIRCLE, SUITE 210<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-20 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>First Tracks Biotherapeutics, Inc. [ TRAX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 31622<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $6.58 | 2026-04-20 |  | A<sup>(2)</sup> |  | 15000 |  | <sup>(3)</sup> | 2027-02-23 | Common Stock | 15000 | $0 | 15000 | D |  |
| Stock Option (right to buy) | $28.03 | 2026-04-20 |  | A<sup>(2)</sup> |  | 6000 |  | <sup>(3)</sup> | 2028-02-01 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $18.43 | 2026-04-20 |  | A<sup>(2)</sup> |  | 6000 |  | <sup>(3)</sup> | 2029-02-07 | Common Stock | 6000 | $0 | 6000 | D |  |
| Stock Option (right to buy) | $4.43 | 2026-04-20 |  | A<sup>(2)</sup> |  | 11000 |  | <sup>(3)</sup> | 2030-02-11 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $7.95 | 2026-04-20 |  | A<sup>(2)</sup> |  | 11000 |  | <sup>(3)</sup> | 2031-02-09 | Common Stock | 11000 | $0 | 11000 | D |  |
| Stock Option (right to buy) | $8.14 | 2026-04-20 |  | A<sup>(2)</sup> |  | 9200 |  | <sup>(3)</sup> | 2032-02-09 | Common Stock | 9200 | $0 | 9200 | D |  |
| Stock Option (right to buy) | $6.22 | 2026-04-20 |  | A<sup>(2)</sup> |  | 10600 |  | <sup>(3)</sup> | 2033-01-05 | Common Stock | 10600 | $0 | 10600 | D |  |
| Stock Option (right to buy) | $5.67 | 2026-04-20 |  | A<sup>(2)</sup> |  | 16510 |  | <sup>(3)</sup> | 2034-01-02 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $3.97 | 2026-04-20 |  | A<sup>(2)</sup> |  | 16510 |  | <sup>(3)</sup> | 2035-01-06 | Common Stock | 16510 | $0 | 16510 | D |  |
| Stock Option (right to buy) | $11.75 | 2026-04-20 |  | A<sup>(2)</sup> |  | 5500 |  | <sup>(4)</sup> | 2036-01-06 | Common Stock | 5500 | $0 | 5500 | D |  |
| Restricted Stock Unit | <sup>(5)</sup> | 2026-04-20 |  | A<sup>(6)</sup> |  | 6030 |  | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 6030 | $0 | 6030 | D |  |
| Restricted Stock Unit | <sup>(5)</sup> | 2026-04-20 |  | A<sup>(6)</sup> |  | 4000 |  | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 4000 | $0 | 4000 | D |  |

---

### Footnotes:

(1) Consists of shares of common stock received in connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") from AnaptysBio, Inc. ("AnaptysBio").

(2) Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

(3) The stock option is fully vested and exercisable.

(4) The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(5) Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

(6) Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement.

(7) The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2026 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

(8) The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

**Signature:** /s/ Ajim Tamboli, Attorney-in-Fact  
**Date:** 2026-04-22

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**